Relenza zanamivir GG167 neuraminidase inhibitor: Phase III data; awaiting approval in Australia

Results of Phase III testing conducted in Australia by partner Glaxo Wellcome showed that

Read the full 146 word article

How to gain access

Continue reading with a
two-week free trial.